PL2721039T3 - Chelatowane inhibitory PSMA - Google Patents

Chelatowane inhibitory PSMA

Info

Publication number
PL2721039T3
PL2721039T3 PL12731239T PL12731239T PL2721039T3 PL 2721039 T3 PL2721039 T3 PL 2721039T3 PL 12731239 T PL12731239 T PL 12731239T PL 12731239 T PL12731239 T PL 12731239T PL 2721039 T3 PL2721039 T3 PL 2721039T3
Authority
PL
Poland
Prior art keywords
psma inhibitors
chelated
chelated psma
inhibitors
psma
Prior art date
Application number
PL12731239T
Other languages
English (en)
Inventor
Clifford BERKMAN
Bea LANGTON-WEBSTER
Xiaobing Wang
Original Assignee
Cancer Targeted Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology Llc filed Critical Cancer Targeted Technology Llc
Publication of PL2721039T3 publication Critical patent/PL2721039T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL12731239T 2011-06-15 2012-06-13 Chelatowane inhibitory PSMA PL2721039T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161497206P 2011-06-15 2011-06-15
US201261647932P 2012-05-16 2012-05-16
EP12731239.5A EP2721039B1 (en) 2011-06-15 2012-06-13 Chelated psma inhibitors
PCT/US2012/042283 WO2012174136A1 (en) 2011-06-15 2012-06-13 Chelated psma inhibitors

Publications (1)

Publication Number Publication Date
PL2721039T3 true PL2721039T3 (pl) 2018-06-29

Family

ID=46420539

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12731239T PL2721039T3 (pl) 2011-06-15 2012-06-13 Chelatowane inhibitory PSMA

Country Status (7)

Country Link
US (3) US9446157B2 (pl)
EP (1) EP2721039B1 (pl)
CN (2) CN103930432B (pl)
CA (1) CA2839195C (pl)
ES (1) ES2657863T3 (pl)
PL (1) PL2721039T3 (pl)
WO (1) WO2012174136A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10717750B2 (en) * 2009-03-19 2020-07-21 The Johns Hopkins University 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012064914A2 (en) * 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma
US9315524B2 (en) * 2012-05-07 2016-04-19 Kumar Ranjan Bhushan Magnetic resonance imaging agents for calcification
WO2013173583A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2842578B1 (en) * 2013-08-27 2018-06-27 GILUPI GmbH Diagnostic device for the detection of biomarkers
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
MX392700B (es) * 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
CN110305187B (zh) * 2019-06-06 2021-02-23 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-NOTA-ANCP-PSMA及其制备方法和应用
CN110305186B (zh) * 2019-06-06 2021-02-23 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2024050440A2 (en) * 2022-08-30 2024-03-07 The Regents Of The University Of California Prostate-specific membrane antigen targeted deep-tumor penetration of polymer nanodrugs and methods of use thereof
WO2025137443A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof
AR134788A1 (es) 2023-12-22 2026-04-01 Rayzebio Inc Radiofármacos dirigidos al receptor 2 de somatostatina y sus usos
WO2026101949A1 (en) 2024-11-06 2026-05-15 Rayzebio, Inc. Compounds targeting carbonic anhydrase ix and uses thereof
WO2026128542A1 (en) 2024-12-11 2026-06-18 Rayzebio, Inc. Radiopharmaceutical compositions targeting glypican-3 and uses thereof
WO2026136824A1 (en) 2024-12-20 2026-06-25 Rayzebio, Inc. Radiopharmaceutical compositions targeting alpha v beta 6 integrin receptor and method of uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545498A4 (en) * 2002-09-06 2006-09-06 Us Gov Health & Human Serv SCAFFOLD-SUBSTITUTED BIFUNCTIONAL DOTA LIGANDS, COMPLEXES AND COMPOSITIONS AND THEIR USE METHODS
PL1999136T3 (pl) * 2006-03-14 2013-03-29 Cancer Targeted Tech Llc Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
DK2187965T3 (da) * 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
WO2012064914A2 (en) 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma

Also Published As

Publication number Publication date
WO2012174136A1 (en) 2012-12-20
CN107325127A (zh) 2017-11-07
ES2657863T3 (es) 2018-03-07
CN103930432A (zh) 2014-07-16
CA2839195A1 (en) 2012-12-20
CN107325127B (zh) 2020-09-01
CN103930432B (zh) 2017-06-23
US20170072075A1 (en) 2017-03-16
US20180207298A1 (en) 2018-07-26
US20140241985A1 (en) 2014-08-28
US9974869B2 (en) 2018-05-22
EP2721039A1 (en) 2014-04-23
CA2839195C (en) 2021-10-26
US10166301B2 (en) 2019-01-01
US9446157B2 (en) 2016-09-20
EP2721039B1 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
PL2710007T3 (pl) Inhibitory kinazy
ZA201307016B (en) Glucosylceramide synthase inhibitors
ZA201404156B (en) Kinase inhibitors
EP2709486A4 (en) TOOL WITH MULTIPLE APPLICATORS
IL229028A0 (en) Kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
ZA201404157B (en) Kinase inhibitors
IL235919A0 (en) inhibitors of fbxo3
ZA201306074B (en) Cathepsin c inhibitors
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201115585D0 (en) Base for construction
GB201018597D0 (en) Inhibitors
SG10201602021WA (en) Glucosylceramide synthase inhibitors
AU339938S (en) Slide